Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Theravance Biopharma (TBPH) EBT: 2013-2025

Historic EBT for Theravance Biopharma (TBPH) over the last 13 years, with Sep 2025 value amounting to -$2.9 million.

  • Theravance Biopharma's EBT rose 71.26% to -$2.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $47.2 million, marking a year-over-year increase of 216.09%. This contributed to the annual value of -$44.6 million for FY2024, which is 9.45% up from last year.
  • Latest data reveals that Theravance Biopharma reported EBT of -$2.9 million as of Q3 2025, which was down 103.95% from $73.2 million recorded in Q2 2025.
  • Over the past 5 years, Theravance Biopharma's EBT peaked at $73.2 million during Q2 2025, and registered a low of -$79.5 million during Q1 2021.
  • Moreover, its 3-year median value for EBT was -$10.1 million (2024), whereas its average is -$3.4 million.
  • Its EBT has fluctuated over the past 5 years, first tumbled by 78.21% in 2024, then skyrocketed by 580.95% in 2025.
  • Over the past 5 years, Theravance Biopharma's EBT (Quarterly) stood at -$58.0 million in 2021, then surged by 75.40% to -$14.3 million in 2022, then spiked by 64.82% to -$5.0 million in 2023, then slumped by 78.21% to -$8.9 million in 2024, then surged by 71.26% to -$2.9 million in 2025.
  • Its EBT stands at -$2.9 million for Q3 2025, versus $73.2 million for Q2 2025 and -$14.1 million for Q1 2025.